Assessing subject diversity by condition and trial phase in clinical trials
- PMID: 35049048
- DOI: 10.1111/ijd.16043
Assessing subject diversity by condition and trial phase in clinical trials
Comment in
-
Prioritization of race and ethnicity reporting and recruitment of diverse participants.Int J Dermatol. 2023 May;62(5):e318-e319. doi: 10.1111/ijd.16253. Epub 2022 May 11. Int J Dermatol. 2023. PMID: 35543242 No abstract available.
Comment on
-
Diversity in Dermatology Clinical Trials: A Systematic Review.JAMA Dermatol. 2017 Feb 1;153(2):193-198. doi: 10.1001/jamadermatol.2016.4129. JAMA Dermatol. 2017. PMID: 28055072
References
-
- Institute of Medicine (US) Committee on Ethical and Legal Issues Relating to the Inclusion of Women in Clinical Studies. NIH Revitalization Act of 1993 Public Law 103-43. Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies: Volume I, 1994. https://www.ncbi.nlm.nih.gov/books/NBK236531/. Accessed August 25, 2020.
-
- Charrow A, Xia FD, Joyce C, Mostaghimi A. Diversity in dermatology clinical trials: a systematic review. JAMA Dermatol 2017; 153: 193-198. https://doi.org/10.1001/jamadermatol.2016.4129
-
- USCS Data Visualizations-CDC. Centers for Disease Control and Prevention. https://gis.cdc.gov/Cancer/USCS/DataViz.html. Accessed October 28, 2020.
-
- Al-Dabagh A, Davis SA, McMichael AJ, Feldman SR. Rosacea in skin of color: not a rare diagnosis. Dermatol Online J 2014; 20: 13030/qt1mv9r0ss.
Publication types
LinkOut - more resources
Full Text Sources
